The proteasome: a suitable antineoplastic target (Q35762448)

10 August 2017

1 reference

title

The proteasome: a suitable antineoplastic target (English)

1 reference

10 August 2017

Julian Adams

1

1 reference

PubMed ID

15122206

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

Nature Reviews Cancer

1 reference

10 August 2017

4

1 reference

10 August 2017

5

1 reference

10 August 2017

349-360

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1361

10 August 2017

0 references

cites work

The Hallmarks of Cancer

1 reference

The ubiquitin-proteasome proteolytic pathway

31 March 2020

1 reference

Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.

31 March 2020

1 reference

Structural features of the 26 S proteasome complex

31 March 2020

1 reference

The proteasome: a new target for novel drug therapies

31 March 2020

1 reference

The proteasome: paradigm of a self-compartmentalizing protease

31 March 2020

1 reference

The ubiquitin-proteasome pathway: on protein death and cell life

31 March 2020

1 reference

The proteasome, a novel protease regulated by multiple mechanisms

31 March 2020

1 reference

Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown

31 March 2020

1 reference

The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides.

31 March 2020

1 reference

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

31 March 2020

1 reference

A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

31 March 2020

1 reference

ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation

31 March 2020

1 reference

Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein

31 March 2020

1 reference

The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes

31 March 2020

1 reference

In vivo characterization of the proteasome regulator PA28

31 March 2020

1 reference

Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus

31 March 2020

1 reference

Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators

31 March 2020

1 reference

A role for the proteasome regulator PA28alpha in antigen presentation

31 March 2020

1 reference

Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta.

31 March 2020

1 reference

Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes

31 March 2020

1 reference

Structural basis for the activation of 20S proteasomes by 11S regulators

31 March 2020

1 reference

KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors

31 March 2020

1 reference

Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol

31 March 2020

1 reference

Changes in intracellular localization of proteasomes in immortalized ovarian granulosa cells during mitosis associated with a role in cell cycle control

31 March 2020

1 reference

Proteasome dynamics during cell cycle in rat Schwann cells

31 March 2020

1 reference

Dynamics of proteasome distribution in living cells

31 March 2020

1 reference

Intracellular localization of proteasomes

31 March 2020

1 reference

Ubiquitin enters the new millennium

31 March 2020

1 reference

A new ticket for entry into budding vesicles-ubiquitin

31 March 2020

1 reference

Protein degradation and protection against misfolded or damaged proteins

31 March 2020

1 reference

Regulation of apoptosis: the ubiquitous way

31 March 2020

1 reference

How proteolysis drives the cell cycle

31 March 2020

1 reference

31 March 2020

Recycling the Cell Cycle

1 reference

Cyclin is degraded by the ubiquitin pathway

31 March 2020

1 reference

Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway

31 March 2020

1 reference

Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation

31 March 2020

1 reference

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

31 March 2020

1 reference

Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing

31 March 2020

1 reference

Rapid destruction of human Cdc25A in response to DNA damage

31 March 2020

1 reference

Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation.

31 March 2020

1 reference

Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation

31 March 2020

1 reference

Arsenite-induced Cdc25C Degradation is through the KEN-box and Ubiquitin-proteasome Pathway

31 March 2020

1 reference

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

31 March 2020

1 reference

The p53 tumor suppressor gene: from molecular biology to clinical investigation.

31 March 2020

1 reference

MDM2--master regulator of the p53 tumor suppressor protein

31 March 2020

1 reference

31 March 2020

1 reference

Regulation of p53 stability by Mdm2

31 March 2020

1 reference

Mdm2 promotes the rapid degradation of p53

31 March 2020

1 reference

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

31 March 2020

1 reference

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53

31 March 2020

1 reference

NF-kappaB in cancer: from innocent bystander to major culprit

31 March 2020

1 reference

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

31 March 2020

1 reference

Inactivation of NF-kappa B inhibitor I kappa B alpha: ubiquitin-dependent proteolysis and its degradation product

31 March 2020

1 reference

Proteasome inhibition: a novel approach to cancer therapy

31 March 2020

1 reference

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

31 March 2020

1 reference

Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally.

31 March 2020

1 reference

Activation of the cell death program by inhibition of proteasome function

31 March 2020

1 reference

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin

31 March 2020

1 reference

Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

31 March 2020

1 reference

Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways

31 March 2020

1 reference

Preferential induction of apoptosis for primary human leukemic stem cells

31 March 2020

1 reference

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

31 March 2020

1 reference

Proteasome inhibitors in the treatment of B-cell malignancies

31 March 2020

1 reference

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

31 March 2020

1 reference

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis

31 March 2020

1 reference

NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells

31 March 2020

1 reference

Proteasome inhibition: a new strategy in cancer treatment

31 March 2020

1 reference

The proteasome: a novel target for cancer chemotherapy

31 March 2020

1 reference

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.

31 March 2020

1 reference

A new structural class of proteasome inhibitors that prevent NF-kappa B activation

31 March 2020

1 reference

Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides

31 March 2020

1 reference

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

31 March 2020

1 reference

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency.

31 March 2020

1 reference

Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors

31 March 2020

1 reference

Proteasome inhibition: a new anti-inflammatory strategy

31 March 2020

1 reference

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

31 March 2020

1 reference

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

31 March 2020

1 reference

Early clinical experience with the novel proteasome inhibitor PS-519.

31 March 2020

1 reference

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

31 March 2020

1 reference

p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts

31 March 2020

1 reference

p53-dependent induction of apoptosis by proteasome inhibitors

31 March 2020

1 reference

Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation.

31 March 2020

1 reference

Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation.

31 March 2020

1 reference

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

31 March 2020

1 reference

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

31 March 2020

1 reference

Clinical update: proteasome inhibitors in solid tumors

31 March 2020

1 reference

NF-kappa B as a therapeutic target in multiple myeloma

31 March 2020

1 reference

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

31 March 2020

1 reference

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

31 March 2020

1 reference

Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB

31 March 2020

1 reference

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

31 March 2020

1 reference

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

31 March 2020

1 reference

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

31 March 2020

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

31 March 2020

1 reference

The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression

31 March 2020

1 reference

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

31 March 2020

1 reference

The proteasome is involved in angiogenesis

31 March 2020

1 reference

Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262.

31 March 2020

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

31 March 2020

1 reference

Platelet-collagen interaction: is GPVI the central receptor?

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1361

1 reference

PubMed ID

15122206

Dimensions Publication ID

10 August 2017

0 references

1 reference

PubMed ID

15122206